甲真菌病外用药的治疗现状及研究进展

中国真菌学杂志　 2018, Vol. 13 　Issue (3): 184-187.

甲真菌病外用药的治疗现状及研究进展

宋娜娜¹, 周晓伟^1,2, 李筱芳^1,2, 刘维达^1,2

1. 中国医学科学院北京协和医学院皮肤病研究所, 南京 210042;
2. 江苏省皮肤病与性病分子生物学重点实验室, 南京 210042

收稿日期:2018-01-15 出版日期:2018-06-28 发布日期:2018-06-28
通讯作者: 李筱芳,E-mail:lxf3568@163.com E-mail:lxf3568@163.com
作者简介:宋娜娜,女(汉族),硕士研究生在读.E-mail:2455707065@qq.com
基金资助:
北京协和医学院协和青年科研基金（2017310033）

The current therapeutics and research progress of topical antifungal agents

SONG Na-na¹, ZHOU Xiao-wei^1,2, LI Xiao-fang^1,2, LIU Wei-da^1,2

1. Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China;
2. Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing 210042, China

Received:2018-01-15 Online:2018-06-28 Published:2018-06-28

摘要/Abstract

摘要：

甲真菌病在人群中广泛存在，初次治愈率低，复发率高，再感染率高。常用治疗方法主要包括局部外用药治疗和系统口服药治疗。口服药因不良反应和药物间的相互作用使其临床应用受限，故近年来治疗研究热点主要集中在外用药。该文综述了外用治疗甲真菌病的传统药物（环吡酮胺甲涂剂、阿莫罗芬甲涂剂）、新型药物（艾氟康唑溶液、tavaborole溶液）以及正在研发中的药物（特比萘芬脂质体、卢立康唑溶液、ME1111、他扎罗汀凝胶）的作用机制、体内外疗效等最新研究进展。

关键词: 甲真菌病, 局部外用药, 作用机制, 研究进展

Abstract:

Onychomycosis is widespread with a low initial treatment rate, high recurrence rate and high re-infection rate. The commonly used methods include topical and oral medications. Due to the side effects and drug-drug interactions of oral antifungal agents, it is mainly focused on the development of topical antifungal antimycotics in recent years. The mechanism, efficiency related to experiments in vitro or vivo and research progress of topical antifungal formulations including traditional drugs (amorolfine and ciclopirox), novel drugs (efinaconazole and tavaborole) and drugs under development (terbinafine hydrochloride, luliconazole, ME1111 and tazarotene) are reviewed in this paper.

Key words: onychomycosis, topical antifungal agents, mechanism, research progress

中图分类号:

R756.4

宋娜娜, 周晓伟, 李筱芳, 刘维达. 甲真菌病外用药的治疗现状及研究进展[J]. 中国真菌学杂志, 2018, 13(3): 184-187.

SONG Na-na, ZHOU Xiao-wei, LI Xiao-fang, LIU Wei-da. The current therapeutics and research progress of topical antifungal agents[J]. Chinese Journal of Mycology, 2018, 13(3): 184-187.

参考文献

[1] Tabara K, Szewczyk AE, Bienias W, et al. Amorolfine vs. ciclopirox-lacquers for the treatment of onychomycosis[J]. Postepy Dermatol Alergol, 2015, 32(1):40-45.
[2] Verrier J, Bontems O, Baudraz-Rosselet F, et al. Oral terbinafine and itraconazole treatments against dermatophytes appear not to favor the establishment of Fusarium spp. in nail[J]. Dermatol Basel Switz, 2014, 228(3):225-232.
[3] Nair AB, Vaka SR, Murthy SN. Transungual delivery of terbinafine by iontophoresis in onychomycotic nail[J]. Drug Dev Ind Pharm, 2011, 37(10):1253-1258.
[4] Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis[J]. J Am Acad Dermatol, 2000,43(4 Suppl):S70-80.
[5] Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly[J]. Clin Exp Dermatol, 1992, 17(Suppl 1):44-49.
[6] Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly[J]. Clin Exp Dermatol, 1992, 17(Suppl 1):41-43.
[7] Sidou, F. and P. Soto.A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers[J]. Int J Tissue React, 2004, 26(1-2):17-24.
[8] Iorizzo M, Hartmane I, Derveniece A, et al. Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis:a randomized, double-blind amorolfine controlled study using a blinded evaluator[J]. Skin Appendage Disord, 2016, 1(3):134-140.
[9] Monti D, Herranz U, Dal Bo L, et al. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs a standard amorolfine lacquer in healthy subjects[J]. J Eur Acad Dermatol Venereol, 2013, 27(2):153-158.
[10] Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis:two phase Ⅲ multicenter, randomized, double-blind studies[J].J Am Acad Dermatol, 2013, 68(4):600-608.
[11] Vlahovic TC, Joseph WS. Efinaconazole topical,10% for the treatment of toenail onychomycosis in patients with diabetes[J].J Drugs Dermatol JDD, 2014, 13(10):1186-1190.
[12] Rich P. Efinaconazole topical solution, 10%:the benefits of treating onychomycosis early[J]. J Drugs Dermatol JDD, 2015, 14(1):58-62.
[13] Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis[J]. J Clin Aesthetic Dermatol, 2015, 8(6):24-29.
[14] Gupta AK, Pillai R. The presence of an air gap between the nail plate and nail bed in onychomycosis patients:treatment implications for topical therapy[J]. J Drugs Dermatol, 2015, 14(8):859-863.
[15] Gupta AK, Versteeg SG. Tavaborole-a treatment for onychomycosis of the toenails[J]. Expert Rev Clin Pharmacol, 2016, 9(9):1145-1152.
[16] Jinna S, Finch J. Spotlight on tavaborole for the treatment of onychomycosis[J].Drug Des Devel Ther, 2015, 9:6185-6190.
[17] Ciaravino V, Coronado D, Lanphear C, et al. Tavaborole, a novel boron-containing small molecule for the topical treatment of onychomycosis,is noncarcinogenic in 2-year carcinogenicity studies[J]. Int J Toxicol, 2014, 33(5):419-427.
[18] Coronado D, Merchant T, Chanda S, et al. In vitro nail penetration and antifungal activity of tavaborole, a boron-based pharmaceutical[J]. J Drugs Dermatol JDD, 2015, 14(6):609-614.
[19] Gupta, A. K. and C. Studholme. Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis[J]. Skin Therapy Lett, 2016, 21(6):7-11.
[20] Tanr?verdi ST, Hilmiolu Polat S, Ye?im Metin D, et al. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis:in vitro and in vivo evaluation[J].J Liposome Res, 2016, 26(2):163-173.
[21] Maeda J, Nanjoh Y, Koga H, et al. In vitro antifungal activity of luliconazole against Trycophyton spp[J]. Med Mycol J, 2016, 57(1):J1-J6.
[22] Gupta AK, Cvetkovi D, Abramovits W, et al. LUZU (luliconazole) 1% cream[J].Skinmed, 2014, 12(2):90-93.
[23] Shimamura T, Miyamae A, Imai A. et al. Comparison of characteristics of two topical therapeutic agents for onychomycosis[J]. Med Mycol J, 2016, 57(4):J141-J147.
[24] Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis:a multicenter, double-blind, randomized phase Ⅲ study[J]. J Dermatol, 2017, 44(7):753-759.
[25] Takahata S, Kubota N, Takei-Masuda N, et al. Mechanism of action of ME1111, a novel antifungal agent for topical treatment of onychomycosis[J]. Antimicrob Agents Chemother, 2016, 60:873-880.
[26] Tabata Y, Takei-Masuda N, Kubota N, et al. Characterization of antifungal activity and nail penetration of ME1111, "a new antifungal agent for topical treatment of onychomycosis"[J]. Antimicrob Agents Chemother, 2016, 60(2):1035-1039.
[27] Hui X, Jung EC, Zhu H, et al. "Antifungal ME1111in vitro human onychopharmacokinetics[J]." Drug Dev Ind Pharm, 2017, 43(1):22-29.
[28] Orlandi A, Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene[J]. J Invest Dermatol, 2004, 122(4):1037-1041.
[29] Campione E, Paterno EJ, Diluvio L, et al. Tazarotene as alternative topical treatment for onychomycosis[J]. Drug Des Devel Ther, 2015, 9:879-886.